The Oncotype DX Breast Recurrence Score® test can provide personalized insights for certain people with breast cancer, whose cancer is:​ Stage I, II, or IIIa​ HR ​ HER2-​ Each patient receives an individualized score to help them make more informed treatment choices.​ Learn more about the Oncotype DX® test: bit.ly/3AXOiBE | Until Everyone Knows

▶️ The Oncotype DX test analyzes the genes of your breast cancer to predict how aggressive it is and whether chemotherapy would help. It helps your doctor personalize your treatment so you can avoid unnecessary chemo if your cancer is less likely to return. Learn more: https://www.primrmed.com/cancer-education/oncotype-dx-for-breast-cancer #breastcancer #oncotypedx #chemotherapy #personalizedtreatment #breastcancerawareness #bcam #patienteducation #simplecancerexplanations #health #cancer #oncol

The Oncotype DX Breast Recurrence Score® test is the only test that has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. And now, the National Comprehensive Cancer Network® (NCCN®) has updated its guidelines and recognized the Oncotype DX® test as the only assay that can be used for prediction of chemotherapy benefit in early-stage breast cancer patients with 1-3 positive axillary lymph nodes. Read more: https://exas.co/3dU3rEB | Exact